The company is leveraging its proprietary Smarticles™ technology to develop a groundbreaking diagnostic platform that enables hospitals and physicians worldwide to swiftly detect infectious diseases. By eliminating the need for enrichment, culture, or sample preparation, GeneWeave's platform provides rapid and accurate measurements of bacterial drug resistance. This transformative solution not only aids in preventing drug-resistant infections but also enhances antibiotic stewardship, ultimately improving patient outcomes in critical bacterial infections.